Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 3700 participants.
Also called NCT01923818
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 3,700 participants
- Sponsor
- Registry
-
NCT01923818
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01923818. Randomized; triple masking; primary purpose treatment. Start 2013-09 (registry gives no type); primary completion 2015-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events
- Acronym
- TRACE
- Condition
- Ischemic Stroke
- Condition
- TIA (transient ischemic attack)
- Intervention (Drug)
- rivaroxaban
- Intervention (Drug)
- Aspirin
- Intervention (Drug)
- placebo
- Lead sponsor
- Xijing Hospital
Record details
- Record id
cardio:ct-nct01923818- Content hash
9cf09b0e853166d0561beee7c21a6e2431c6725a184b57425a3061af909f172b